Boston Scientific BSX
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on BSX
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on BSX.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
BSX at a glance
Shares of Boston Scientific are down 4.23% at $42.75. The company is worth $61.96B, number 358 out of 3753 on our list.
It is close to the bottom of its 52-week range ($39.57 to $105.65), 59.5% under the high. Holders are behind 57.3% over twelve months, and down 15.3% across the last three months.
On the chart it has slipped under both the 50-day ($44.33) and 200-day ($55.36) moving averages; RSI is 45, and the last 30 sessions moved at roughly 39% annualized volatility.
For the quarter ended Sep 2026 it reported $5.14B in revenue, up 1.4% from a year earlier, with $580.00M of net profit (a 16.6% margin).
Buyers are paying 18.0 times trailing earnings, 73% below its five-year average of 66.3. The median for its industry group is 25.1.
22 analysts follow the stock and the average call is "buy". The mean target, $50.05, sits 17.1% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 3 factors below, ranked against the 3741 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
22 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
BSX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (203.8% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $50.05, 17.1% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $49.00, so shares trade 12.8% below that estimate. On earnings multiple, it sits in the 1st percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Boston Scientific: the business
Boston Scientific makes catheters, stents, heart-rhythm devices and other tools used in minimally invasive procedures.
What tends to move it. Growth in its electrophysiology and Watchman heart devices is the main story, along with procedure volumes at hospitals.
Where the case gets weaker. Boston Scientific's growth case leans heavily on electrophysiology and Watchman adoption continuing at a fast clip, so any slowdown in hospital procedure volumes or new competition in heart-rhythm devices would remove the main driver behind recent results. A pause in hospital capital spending would also slow adoption of newer, higher-margin device categories.
Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -3.3% | Bearish |
| Price vs 50-day average | -3.6% | Bearish |
| Price vs 200-day average | -22.8% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 44.9 | Bearish |
| MACD (12,26,9) | -0.13 | Bearish |
| Bollinger band position | 20% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 6, 2026 9:50 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
How BSX ranks on BeStock
Ranks are among the 3,741 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 18.0x earnings, BSX looks about mid-pack against the market, and trades 28% below the 25.1x median among Medical Devices names. The two comparisons do not always agree.
BSX stock: common questions
How is Boston Scientific stock doing today?
$42.75 is the latest print for BSX, a move of -4.23% against yesterday's close of $44.64. Today's low and high so far: $42.69 and $43.63.
How big is Boston Scientific?
Equity value comes to $61.96B at the current price. By that measure it is number 358 of the 3753 names in our coverage.
Is BSX expensive on earnings?
Buyers pay 18.0 times the last twelve months of profit (EPS $1.94). Averaged over five years the multiple has been 66.3, and today's level ranks in the 1st percentile of its own history.
How far is BSX from its yearly high?
The year's floor is $39.57 and the ceiling $105.65. Shares are 59.5% away from that ceiling.
Are there dividends on Boston Scientific shares?
Our data shows no dividend paid by Boston Scientific over the trailing twelve months.
What is the analyst view on Boston Scientific?
Of 22 analysts, 64% say buy, 36% hold and 0% sell. Price targets average $50.05, with the most cautious at $44.00 and the most optimistic at $60.00.
What does Boston Scientific do?
Boston Scientific makes catheters, stents, heart-rhythm devices and other tools used in minimally invasive procedures.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on BSX.
Sign in to join the discussion.